Skye Bioscience (SKYE) Retained Earnings (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Retained Earnings of -$199.4 million for Q1 2026, down 40.36% year-over-year from -$334.3 million in Q1 2025, and down 6.69% quarter-over-quarter from -$186.9 million in Q4 2025.
Skye Bioscience (SKYE) Retained Earnings (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Retained Earnings for 15 consecutive years, with -$199.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 40.36% year-over-year to -$199.4 million; the TTM figure through Mar 2026 stood at -$199.4 million (down 40.36% YoY), while the FY2025 annual figure was -$186.9 million, down 42.71% from the prior year.
- Retained Earnings retreated to -$199.4 million in Q1 2026 per SKYE's latest filing, from -$186.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$50.3 million in Q1 2022 and bottomed at -$199.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$112.8 million across 5 years, with a median of -$109.4 million in 2024.
- Annual changes were most pronounced in 2023 — Retained Earnings slumped 75.85% — and 2024, when it retreated 21.25%.
- Skye Bioscience's Retained Earnings stood at -$66.7 million in 2022, then sank by 56.41% to -$104.4 million in 2023, then retreated by 25.45% to -$130.9 million in 2024, then tumbled by 42.71% to -$186.9 million in 2025, then slipped by 6.69% to -$199.4 million in 2026.
- Business Quant data shows SKYE's Retained Earnings at -$199.4 million in Q1 2026, -$186.9 million in Q4 2025, and -$172.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 4.38 Bn |
| 10 | Skye Bioscience | 10.66 Mn | 10.66 Mn | - | -210.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -199.38 Mn |
| Dec 31, 2025 | -186.87 Mn |
| Sep 30, 2025 | -172.43 Mn |
| Jun 30, 2025 | -159.68 Mn |
| Mar 31, 2025 | -142.05 Mn |
| Dec 31, 2024 | -130.95 Mn |
| Sep 30, 2024 | -121.20 Mn |
| Jun 30, 2024 | -117.30 Mn |
| Mar 31, 2024 | -109.40 Mn |
| Dec 31, 2023 | -104.38 Mn |
| Sep 30, 2023 | -99.96 Mn |
| Jun 30, 2023 | -75.02 Mn |
| Mar 31, 2023 | -71.91 Mn |
| Dec 31, 2022 | -66.74 Mn |
| Sep 30, 2022 | -56.85 Mn |
| Jun 30, 2022 | -53.72 Mn |
| Mar 31, 2022 | -50.30 Mn |
| Dec 31, 2021 | -47.26 Mn |
| Sep 30, 2021 | -44.74 Mn |
| Jun 30, 2021 | -42.92 Mn |